Keyphrases
Gene Expression
100%
Hepatocellular Carcinoma
100%
Molecular Targeted Therapy
100%
Patient Stratification
100%
Actionable Genes
100%
Tumor
66%
Platelet-derived Growth Factor Receptor (PDGFR)
50%
MRNA Expression
33%
Mammalian Target of Rapamycin (mTOR)
33%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
33%
Fibroblast Growth Factor Receptor 1 (FGFR1)
33%
Molecular Targeted Agents
33%
BCLC Staging
33%
Real-time RT-PCR
16%
MRNA Level
16%
Target Molecule
16%
Expression Analysis
16%
High-level Expression
16%
Cancer Patients
16%
In Cancer
16%
Nontumor
16%
Therapeutic Strategies
16%
Clinical Trials
16%
Combination Therapy
16%
C-Raf
16%
Sorafenib
16%
Cluster Analysis
16%
Tumoral
16%
Distinct Subtypes
16%
Low Expression
16%
Hepatocellular Carcinoma Patients
16%
Hepatocellular Carcinoma Cells
16%
Targeted Drugs
16%
Companion Diagnostics
16%
Sorafenib Treatment
16%
In Vitro Sensitivity
16%
Targeted Combination
16%
Medicine and Dentistry
Gene Expression
100%
Hepatocellular Carcinoma
100%
Molecularly Targeted Therapy
100%
Neoplasm
62%
Messenger RNA
50%
Upregulation
25%
Mammalian Target of Rapamycin
25%
Epidermal Growth Factor Receptor
25%
Sorafenib
25%
Fibroblast Growth Factor Receptor 1
25%
Quantitative Reverse Transcription Polymerase Chain Reaction
12%
Diagnosis
12%
In Vitro
12%
Clinical Trial
12%
Cluster Analysis
12%
Combination Therapy
12%
Carcinoma Cell
12%
Expression Analysis
12%
Biochemistry, Genetics and Molecular Biology
Gene Expression
100%
Messenger RNA
100%
Epidermal Growth Factor Receptor
50%
Upregulation
50%
Mammalian Target of Rapamycin
50%
Fibroblast Growth Factor Receptor 1
50%
Sorafenib
50%
Quantitative Reverse Transcription Polymerase Chain Reaction
25%
Expression Analysis
25%
Clinical Trial
25%
Cluster Analysis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Neoplasm
62%
Messenger RNA
50%
Epidermal Growth Factor Receptor
25%
Sorafenib
25%
Fibroblast Growth Factor Receptor 1
25%
Malignant Neoplasm
12%
Combination Therapy
12%
Clinical Trial
12%